



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

<http://www.wjgnet.com>

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10300

Title: Effects of GLP-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Reviewer code: 00503618

Science editor: Yuan Qi

Date sent for review: 2014-03-26 21:12

Date reviewed: 2014-03-27 04:33

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a very nice literature review on the subject. There are two missing items. The first is a disclosure by the authors that they have no relationship with any of the manufacturers that produce GLP-1 receptor agonists. The second missing item is a table that summarizes all of these important findings. It would greatly enhance this excellent manuscript.

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10300

Title: Effects of GLP-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Reviewer code: 01551804

Science editor: Yuan Qi

Date sent for review: 2014-03-26 21:12

Date reviewed: 2014-04-08 20:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Wang et al. Effect of GLP-1 receptor antagonist on non-alcoholic fatty liver disease and inflammation. (MS ID: 10300) The authors described the clinical importance of GLP-1 and reviewed the effect of GLP-1RA on NAFLD. They also summarized various aspects of its mechanisms. The manuscript is well written and valuable for publication in World Journal of Gastroenterology; however, there are a few points of concern that preclude the manuscript from being accepted in the journal. The authors described the epidemiology of NAFLD in the "Conclusions"; however, this should be included in the "Introduction". The authors reviewed the various mechanisms of GLP-1RA on NAFLD as well as anti-inflammation effects. Although the complicated mechanisms were summarized well in detail in the text, they should use figures to let the readers understand them more correctly.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10300

Title: Effects of GLP-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Reviewer code: 00503575

Science editor: Yuan Qi

Date sent for review: 2014-03-26 21:12

Date reviewed: 2014-04-09 19:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input checked="" type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review article describe the Glucagon-like peptide1 (GLP-1) in NAFLD. It also describe NAFLD-associated effects of GLP-1RA in animal models and clinical trials in patients with T2DM or obesity. While the topic is of importance, some issue need to be addressed. As the text do not include pages, the reviewer refer to pages starting from the author page (page 1). ? In the introduction, the authors claimed "We modified GLP-1 to Glucagon-like peptide-1 receptor agonists (GLP-1RA), which has a prolonged half-life and can be administered on a once daily basis [3]." This reference did not refer to a work done by the authors. This sentence should be either reformulated or provide other reference. ? Page 4: "In addition, the GLP-1RA can enhance insulin sensitivity, promote insulin secretion, and reduce lipid metabolism indirectly." This sentence need a reference. ? Page 5: "GLP-1RA changed body composition, as patients treated with liraglutide showed a decrease in total body mass and total fat mass and the loss in fat mass accounted for most of the loss of total body mass [24]." This sentence need to be reformulated. ? The citation of authors et al need to be re-verified through the text. The position of references [] need to be re-verified through the text. For example: o in page 6: ovoid to mention the authors initials in the text such as in Sathyanarayana P et al... o in page 7 Nitika A. Gupta et al [35] should be Gupta et al. o In page 7 the mention of references [36] [39] should be [36,39]. ? In page 8, in the sentence "NAFLD can progress from simple fatty liver fatty hepatitis to fatty liver fibrosis and fatty liver cirrhosis.", the word fatty has been used 4 times ? The GLP-1 receptor agonist should be abbreviated through the text.